TMO insider exercises 2,975 options, sells at $580; holds 21,152

Q: How many Thermo Fisher (TMO) options were exercised?

The officer exercised 725 options at $253.99 and 2,250 options at $294.02 .

Q: How many TMO shares were sold and at what price?

The officer sold 725 shares and 2,250 shares at $580 per share.

Q: What are the officer’s TMO holdings after the transactions?

Beneficial ownership was 21,152.223 shares, held directly, after the reported trades.

Q: When did the exercised options vest?

The options vested in four equal installments ending on 02/26/2023 and 09/05/2023 , respectively.

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Thermo Fisher Scientific (TMO) reported insider transactions by an Executive Vice President on 11/10/2025 under a Rule 10b5-1 trading plan. The officer exercised 725 options at $253.99 and 2,250 options at $294.02, then sold 725 shares and 2,250 shares at $580.

Following these transactions, the officer beneficially owned 21,152.223 shares of common stock, held directly. The options exercised were previously granted and had vested in four equal annual installments ending in 2023.

Insider Trade Summary

Net Seller: 2,975 shares ($1,725,500)

Net Sell 6 txns

Insider Pettiti Gianluca

Role Executive Vice President

Sold 2,975 shs ($1.73M)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	725	$0.00	--
Exercise	Stock Option (Right to Buy)	2,250	$0.00	--
Exercise	Common Stock	725	$253.99	$184K
Sale	Common Stock	725	$580.00	$421K
Exercise	Common Stock	2,250	$294.02	$662K
Sale	Common Stock	2,250	$580.00	$1.30M

Holdings After Transaction: Stock Option (Right to Buy) — 0 shares (Direct); Common Stock — 21,877.223 shares (Direct)

Footnotes (1)

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 10, 2025. The option vested in four equal installments on February 26, 2020, 2021, 2022 and 2023. The option vested in four equal installments on September 5, 2020, 2021, 2022, and 2023.

Form 4 Insider Transactions: What Each Field Means →

11/12/2025 - 04:36 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pettiti Gianluca

(Last)

(First)

(Middle)

168 THIRD AVENUE

(Street)

WALTHAM

02451

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
THERMO FISHER SCIENTIFIC INC. [ TMO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Executive Vice President

3. Date of Earliest Transaction (Month/Day/Year)
11/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/10/2025		M		725	A	$253.99	21,877.223	D
Common Stock	11/10/2025		S⁽¹⁾		725	D	$580	21,152.223	D
Common Stock	11/10/2025		M		2,250	A	$294.02	23,402.223	D
Common Stock	11/10/2025		S⁽¹⁾		2,250	D	$580	21,152.223	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$253.99	11/10/2025		M			725	⁽²⁾	02/26/2026	Common Stock	725	$0	0	D
Stock Option (Right to Buy)	$294.02	11/10/2025		M			2,250	⁽³⁾	09/05/2026	Common Stock	2,250	$0	0	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 10, 2025.

2. The option vested in four equal installments on February 26, 2020, 2021, 2022 and 2023.

3. The option vested in four equal installments on September 5, 2020, 2021, 2022, and 2023.

	/s/ Melodie T. Morin, Attorney-in-Fact for Gianluca Pettiti	11/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider activity did TMO disclose?

An Executive Vice President exercised options and sold shares on 11/10/2025 pursuant to a Rule 10b5-1 plan.

How many Thermo Fisher (TMO) options were exercised?

The officer exercised 725 options at $253.99 and 2,250 options at $294.02.

How many TMO shares were sold and at what price?

The officer sold 725 shares and 2,250 shares at $580 per share.

What are the officer’s TMO holdings after the transactions?

Beneficial ownership was 21,152.223 shares, held directly, after the reported trades.

Were the sales under a 10b5-1 plan?

Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan adopted on February 10, 2025.

When did the exercised options vest?

The options vested in four equal installments ending on 02/26/2023 and 09/05/2023, respectively.